Why Lilly And Novo Nordisk Will Keep Dominating The Market For Blockbuster GLP-1 Drugs

  • 📰 ForbesTech
  • ⏱ Reading Time:
  • 38 sec. here
  • 11 min. at publisher
  • 📊 Quality Score:
  • News: 49%
  • Publisher: 59%

Lilly News

Novo Nordisk,Ozempic,Wegovy

Alex Knapp is a senior editor at Forbes covering healthcare, science, and cutting edge technology who joined Forbes in 2011. He's written dozens of profiles of entrepreneurs across a variety of fields and done deep dives into technological trends from superconductors to space travel to pharmaceuticals.

Despite supply shortages, the drugs by the two companies saw their sales surge in the first quarter of the year, and competitors are still trying to catch up.t’s not often that a class of chemical becomes a household name, but glucagon-like peptide-1, aka GLP-1, has achieved that status.

Jørgensen said he’s not too concerned about the competition yet. By the time a company gets to late-stage clinical trials, “you’re already too late,” he said. “It takes several years to build the kind of capacity you’re dealing with here, so it’s a daunting task to get it all in place.” Both companies are also looking to refine and develop what they hope are new and better versions. Lilly has new obesity drugs in its clinical development pipeline, including a monoclonal antibody treatment for obesity, as well as another potential new treatment that’s a different class of drug than GLP-1s but behaves similarly.with biotech company Metaphore to develop two new therapeutics in a deal potentially worth up to $600 million.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 318. in US

United States United States Latest News, United States United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Why Eli Lilly's earnings are no sure thing for traders despite obesity drug momentumThe Food and Drug Administration said supplies of Zepbound and Mounjaro are expected to be limited through the second quarter, for all but one dosage.
Source: CNBC - 🏆 12. / 72 Read more »

Buffett's 2024 Investment Wisdom: Psychology Matters As Much As FinancialsI am the editor of three Forbes investment newsletters: Forbes Dividend Investor, Forbes Billionaire Investor and covered call writing advisory service, Forbes Premium Income Report. Prior to joining Forbes in 2001, I was a producer and reporter at CNN Financial News, focusing on stories about entrepreneurship.
Source: Forbes - 🏆 394. / 53 Read more »